Obesity Today—March 3, 2026

This week’s Obesity update highlights real-world care-model outcomes, early-stage modality expansion, China-driven clinical and commercial momentum, and competitive lifecycle strategies spanning oral delivery, microneedles, and biosimilars.

In this Newsletter

Dive deeper

🧑‍⚕️ knownwell reports real-world obesity outcomes and durability [1] [US • 24 Feb 2026]

https://www.prnewswire.com/news-releases/knownwell-demonstrates-improved-obesity-outcomes-and-long-term-durability-in-first-clinical-outcomes-report-302695268.html
Context: Real-world analysis of 1,807 patients treated Feb 2023–Feb 2025, with 12-month follow-up and SECA body composition comparisons (benchmark source not specified).
Key point: knownwell reported average weight loss, durability over 12 months, and lower lean-mass loss versus published GLP-1 trial averages (specific comparator trials not named).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Bloom Science doses first patient in Phase 1b obesity study of BL-001 [2] [Australia • 24 Feb 2026]

https://www.prnewswire.com/news-releases/bloom-science-initiates-phase-1b-obesity-trial-of-bl-001-advancing-a-differentiated-approach-beyond-glp-1-302694371.html
Context: BL-001-1201 is randomized, double-blind, placebo-controlled, up to 48 adults with obesity, daily oral dosing for 12 weeks, two sites in Australia.
Key point: Bloom Science initiated Phase 1b to assess safety, tolerability, and weight loss effects for BL-001 (an oral live biotherapeutic product positioned to mimic ketogenic-diet metabolic effects).
Implication: Signals pipeline investment and modality expansion.

💉 Novo Nordisk-partnered UBT251 posts Phase II China weight-loss result [3] [China • 25 Feb 2026]

https://www.clinicaltrialsarena.com/news/novo-nordisk-partnered-drug-shows-19-7-weight-loss-in-phase-ii-trial/
Context: ChiCTR2500113817, 24-week treatment, three dose arms versus placebo, triple agonist (GLP-1, GIP, glucagon).
Key point: United Bio-Technology (United Laboratories) and Novo Nordisk reported Phase II data in China, with the highest-dose arm showing 19.7% weight loss versus 2.0% on placebo, GI AEs were most common.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Rhythm shares additional Phase 3 TRANSCEND data for setmelanotide in acquired hypothalamic obesity [4] [US • 01 Mar 2026]

https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-additional-positive-data-phase
Context: Global Phase 3 TRANSCEND, 52-week data, includes Japanese cohort additions and supplemental patients beyond the pivotal cohort; FDA PDUFA goal date stated as 20 Mar 2026.
Key point: Rhythm reported additional positive efficacy and hunger-score data for setmelanotide in acquired hypothalamic obesity and said it plans to submit the final data package to FDA on 02 Mar 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Pfizer China adds Sciwind Biosciences as partner for ecnoglutide commercialization [5] [China • 24 Feb 2026]

https://www.forbes.com/sites/russellflannery/2026/02/24/pfizer-adds-sciwind-as-china-partner-for-new-weight-loss-drug/
Context: Collaboration framed as China-focused commercialization; deal value cited as up to $495 million (as reported by the source).
Key point: Pfizer China and Hangzhou Sciwind Biosciences announced a commercialization collaboration for ecnoglutide (weight management and diabetes positioning, trial specifics not provided in the source excerpt).
Implication: Signals pipeline investment and modality expansion.

💊 Novo Nordisk and Vivtex partner on oral delivery tech for obesity and diabetes biologics [6] [8] [US • 25 Feb 2026]

https://www.globenewswire.com/news-release/2026/02/25/3244528/0/en/Novo-Nordisk-and-Vivtex-partner-to-develop-next-generation-oral-medicines-for-obesity-and-diabetes.html
Context: Licensing of select oral drug-delivery technologies, Novo Nordisk to lead global development and commercialization for resulting products (asset names not specified).
Key point: Novo Nordisk and Vivtex announced a partnership, with Vivtex eligible for upfront, research funding, and milestones totaling up to $2.1B plus tiered royalties, to advance next-generation oral biologics for obesity and diabetes.
Implication: Signals pipeline investment and modality expansion.

🩹 Daewoong licenses microneedle technology for obesity and metabolic disease products [7] [South Korea • 25 Feb 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=30720
Context: Daewoong Pharmaceutical licenses microneedle tech from affiliate Daewoong Therapeutics; semaglutide microneedle patch said to be in Phase 1 (per source).
Key point: Daewoong Pharmaceutical said it secured global exclusive rights to develop and commercialize microneedle-based products, including obesity and metabolic disease targets, positioning patches as an alternative delivery format (weekly use claimed by the company).
Implication: Signals pipeline investment and modality expansion.

🧬 Jiuyuan seeks approval for Wegovy (semaglutide) biosimilar in China [9] [China • 26 Feb 2026]

https://www.bioworld.com/articles/729245-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china?v=preview
Context: Regulatory acceptance for review is an early procedural milestone (approval timing not stated).
Key point: BioWorld reported China’s NMPA accepted Jiuyuan Genetic Biopharmaceutical’s application for Jikeqin, described as a biosimilar to Novo Nordisk’s Wegovy (semaglutide) for obesity.
Implication: Introduces competition that may affect pricing and formulary access.

📄 Sam Chun Dang Pharm cites Europe deal for “oral Wegovy” positioning [10] [EU • 27 Feb 2026]

https://biz.chosun.com/en/en-finance/2026/02/27/XPQNY7JKOVFS5EH42THK2CVBUM/
Context: Deal described as a technology transfer, exclusive license, and commercialization master agreement across 11 European countries (counterparty not named by the source excerpt).
Key point: Chosun Biz reported Sam Chun Dang Pharm signed a deal valued at 5.3 trillion won for a generic “oral Wegovy” commercialization arrangement, including upfront and milestone payments and a profit-share structure (development and regulatory specifics not provided).
Implication: Signals pipeline investment and modality expansion.

Why it matters

Obesity care is shifting from single-drug narratives to delivery formats and care models, including hybrid clinics, oral biologics enablement, and microneedle patches.
China remains central for both clinical data generation and commercialization partnerships, with multiple regulatory and business milestones in one week.
Competitive pressure is expanding beyond GLP-1 class leaders into multi-agonists, new modalities (LBPs), and lifecycle strategies (oral delivery, biosimilars).
Near-term regulatory readouts (Rhythm’s PDUFA date) can reshape rare-disease obesity segments and payer attention.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

FAQ

What did knownwell claim in its Clinical Outcomes Report, and what kind of evidence is it?

knownwell reported real-world outcomes from its patient cohort, including durability and body composition claims (observational, not a randomized trial in the source). Findings are attributed to the company report and comparisons to published benchmarks (specific benchmarks not named). [1]

What is BL-001 (Bloom Science), and what is being tested in Phase 1b?

BL-001 is described as an oral live biotherapeutic product designed to replicate key metabolic effects of the ketogenic diet. The Phase 1b trial tests safety, tolerability, and weight loss effects over 12 weeks in adults with obesity. [2]

What is UBT251, and what result was reported in China?

UBT251 is a triple agonist targeting GLP-1, GIP, and glucagon receptors, co-developed by United Bio-Technology (United Laboratories) and Novo Nordisk. The source reports 19.7% weight loss at the highest dose versus 2.0% on placebo after 24 weeks (China Phase II). [3]

What is setmelanotide being evaluated for in Rhythm’s TRANSCEND trial, and what is the timeline?

Setmelanotide is being evaluated for acquired hypothalamic obesity in the Phase 3 TRANSCEND trial. Rhythm stated an FDA PDUFA goal date of 20 Mar 2026 and described additional positive 52-week data. [4]

What is the Novo Nordisk–Vivtex deal actually about?

It is a licensing partnership for Vivtex oral drug-delivery technologies intended to enable oral delivery of biologic drug candidates for obesity and diabetes, with up to $2.1B in potential payments plus royalties (assets not specified). [6], [8]

What is the Jiuyuan filing, and why does “accepted for review” matter?

BioWorld reported that China’s NMPA accepted Jiuyuan’s application for review for a Wegovy (semaglutide) biosimilar. Acceptance signals the dossier has entered the agency’s review process, not that approval is granted. [9]

Entities / Keywords

knownwell (hybrid obesity care, metabolic health clinic model, real-world outcomes)
Bloom Science (BL-001, live biotherapeutic product, ketogenic biology, Phase 1b)
Novo Nordisk (UBT251 partnership, Vivtex oral delivery tech, obesity, diabetes)
United Laboratories, United Bio-Technology (UBT251, triple agonist, China trials)
Rhythm Pharmaceuticals (setmelanotide, TRANSCEND, acquired hypothalamic obesity, MC4R pathway)
Pfizer China, Sciwind Biosciences (ecnonglutide, China commercialization)
Vivtex (oral biologics delivery, GI screening, formulation platform)
Daewoong Pharmaceutical, Daewoong Therapeutics (microneedle patch, semaglutide patch, GLP-1 delivery)
Jiuyuan Genetic Biopharmaceutical (Jikeqin, Wegovy biosimilar, NMPA review)
Sam Chun Dang Pharm (Europe commercialization deal, “oral Wegovy” generic positioning)